This RSA section is an unofficial mirror, is not legal advice, and may be incomplete, outdated, or incorrectly processed.

RSA 126-X:1 · Definitions

126-X:1 Definitions. – In this chapter:

Copy link
I.

"Alternative treatment center" means a not-for-profit entity registered under RSA 126-X:7 that acquires, possesses, cultivates, manufactures, delivers, transfers, transports, sells, supplies, and dispenses cannabis, and related supplies and educational materials, to qualifying patients, designated caregivers, other alternative treatment centers, and visiting qualifying patients.

Copy link
II.

"Alternative treatment center agent" means a principal officer, board member, employee, manager, or volunteer of an alternative treatment center who is 21 years of age or older and has not been convicted of a felony or any felony drug-related offense.

Copy link
III.

"Cannabis" means all parts of any plant of the Cannabis genus of plants, whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, salt, derivative, mixture, or preparation of such plant, its seeds, or resin. Such term shall not include the mature stalks of such plants, fiber produced from such stalks, oil, or cake made from the seeds of such plants, any other compound, salt, derivative, mixture, or preparation of such mature stalks (except the resin extracted therefrom), fiber, oil or cake, or the sterilized seeds of such plants which are incapable of germination. In this chapter, cannabis shall not include hemp grown, processed, marketed, or sold under RSA 439-A.

Copy link
IV.

"Cultivation location" means a locked and enclosed site, under the control of an alternative treatment center where cannabis is cultivated, secured with one or more locks or other security devices in accordance with the provisions of this chapter.

Copy link
V.

"Department" means the department of health and human services.

Copy link
VI.

"Designated caregiver" means an individual who:

Copy link
(a)

Is at least 21 years of age;

Copy link
(b)

Has agreed to assist with one or more (not to exceed 5) qualifying patient's therapeutic use of cannabis, except if the qualifying patient and designated caregiver each live greater than 50 miles from the nearest alternative treatment center, in which case the designated caregiver may assist with the therapeutic use of cannabis for up to 9 qualifying patients;

Copy link
(c)

Has never been convicted of a felony or any felony drug-related offense; and

Copy link
(d)

Possesses a valid registry identification card issued pursuant to RSA 126-X:4. VI-a. "Facility caregiver" means a residential care facility, nursing home, hospital, or hospice house licensed under RSA 151 which has agreed to allow one or more qualifying patients who are residents or patients of the facility to utilize therapeutic cannabis obtained by the resident or the resident's designated caregiver from an alternative treatment center, and which has agreed to assist such residents in the therapeutic use of their cannabis in accordance with a policy developed by the facility, and in accordance with rules adopted by the commissioner of health and human services pursuant to RSA 541-A. "Facility caregiver" shall also include community living facilities certified under RSA 126-A:19 and RSA 126-A:20.

Copy link
VII.

(a) "Provider" means:

Copy link
(1)

A physician licensed to prescribe drugs to humans under RSA 329 and who possesses an active registration from the United States Drug Enforcement Administration to prescribe controlled substances;

Copy link
(2)

An advanced practice registered nurse licensed pursuant to RSA 326-B:18 and who possesses an active registration from the United States Drug Enforcement Administration to prescribe controlled substances;

Copy link
(3)

A physician, physician associate, or advanced practice registered nurse licensed to prescribe drugs to humans under the relevant state licensing laws in Maine, Massachusetts, or Vermont and who possesses an active registration from the United States Drug Enforcement Administration to prescribe controlled substances and who is primarily responsible for the patient's care related to his or her qualifying medical condition;

Copy link
(4)

A physician associate licensed pursuant to RSA 328-D and who possesses an active registration from the United States Drug Enforcement Administration to prescribe controlled substances consistent with his or her collaboration agreement; or

Copy link
(5)

Any other New Hampshire provider who is licensed to prescribe drugs to humans and who possesses an active registration from the United States Drug Enforcement Administration to prescribe controlled substances and who is primarily responsible for the patient's care related to his or her qualifying medical condition.

Copy link
(b)

For a visiting qualifying patient, "provider" means an individual licensed to prescribe drugs to humans in the state of the patient's residence and who possesses an active registration from the United States Drug Enforcement Administration to prescribe controlled substances.

Copy link
VIII.

"Provider-patient relationship" means a medical relationship between a licensed provider and a patient that includes an in-person exam, a history, a diagnosis, and a treatment plan appropriate for the licensee's medical specialty.

Copy link
IX.

(a) "Qualifying medical condition" means the presence of:

Copy link
(1)

Cancer, glaucoma, positive status for human immunodeficiency virus, acquired immune deficiency syndrome, hepatitis C, amyotrophic lateral sclerosis, muscular dystrophy, Crohn's disease, multiple sclerosis, chronic pancreatitis, spinal cord injury or disease, traumatic brain injury, epilepsy, lupus, Parkinson's disease, Alzheimer's disease, ulcerative colitis, Ehlers-Danlos syndrome, or one or more injuries or conditions that has resulted in one or more qualifying symptoms under subparagraph (2); and

Copy link
(2)

A severely debilitating or terminal medical condition or its treatment that has produced at least one of the following: elevated intraocular pressure, cachexia, chemotherapy-induced anorexia, wasting syndrome, agitation of Alzheimer's disease, severe pain, constant or severe nausea, moderate to severe vomiting, seizures, severe, persistent muscle spasms, or moderate to severe insomnia; or

Copy link
(b)

"Qualifying medical condition" also means:

Copy link
(1)

Moderate to severe chronic pain.

Copy link
(2)

Severe pain.

Copy link
(3)

Moderate or severe post-traumatic stress disorder.

Copy link
(4)

Autism spectrum disorder in adults 21 years of age or older.

Copy link
(5)

Autism spectrum disorder in people under 21 years of age with the requirement of a consultation with a certified provider of child and/or adolescent psychiatry, developmental pediatrics, or pediatric neurology, who confirms that the autism spectrum disorder has not responded to previously prescribed medication or for which other treatment options produced serious side effects and who supports certification for the use of therapeutic cannabis.

Copy link
(6)

Opioid use disorder, with the following restrictions:

Copy link
(A)

When certified only by a board certified addiction medicine or addiction psychiatry provider who is actively treating the patient for opioid use disorder; and

Copy link
(B)

With associated symptoms of cravings and/or withdrawal.

Copy link
(7)

Generalized anxiety disorder.

Copy link
(8)

For adults 21 years of age or older, any debilitating or terminal medical condition or symptom for which the potential benefits of using therapeutic cannabis would, in the provider's clinical opinion, likely outweigh the potential health risks for the patient. In order to certify a patient under this category, a certifying provider shall include on the written certification the patient's specific condition or symptom and attest to their clinical opinion.

Copy link
X.

"Qualifying patient" means a resident of New Hampshire who has been diagnosed by a provider as having a qualifying medical condition and who possesses a valid registry identification card issued pursuant to RSA 126-X:4.

Copy link
XI.

"Registry identification card" means a document indicating the date issued, effective date, and expiration date by the department pursuant to RSA 126-X:4 that identifies an individual as a qualifying patient or a designated caregiver.

Copy link
XII.

"Seedling" means a cannabis plant that has no flowers and is less than 12 inches in height and less than 12 inches in diameter.

Copy link
XIII.

"Therapeutic use" means the acquisition, possession, cultivation, preparation, use, delivery, transfer, or transportation of cannabis or paraphernalia relating to the administration of cannabis to treat or alleviate a qualifying patient's qualifying medical condition or symptoms or results of treatment associated with the qualifying patient's qualifying medical condition. It shall not include:

Copy link
(a)

The use of cannabis by a designated caregiver who is not a qualifying patient; or

Copy link
(b)

Cultivation or purchase by a visiting qualifying patient from a qualifying patient or designated caregiver; or

Copy link
(c)

Cultivation by a designated caregiver or qualifying patient.

Copy link
XIV.

"Unusable cannabis" means any cannabis, other than usable cannabis, including the seeds, stalks, and roots of the plant.

Copy link
XV.

"Usable cannabis" means the dried leaves and flowers of the cannabis plant and any mixture or preparation thereof, but does not include the seeds, stalks, and roots of the plant and does not include the weight of any non-cannabis ingredients combined with cannabis and prepared for consumption as food or drink. XV-a. "Use in adolescence" means the therapeutic use of cannabis by any person whose age is within the generally accepted medical and psychiatric definition of an adolescent as ranging in age from 12-25 years old, as well as by individuals younger in age.

Copy link
XVI.

"Visiting qualifying patient" means a person who is not a resident of New Hampshire, or who has been a resident of New Hampshire for fewer than 90 days, who has been issued a valid registry identification card, or its equivalent, under the laws of another state, district, territory, commonwealth, or insular possession of the United States, or under the laws of Canada, that allows, in the jurisdiction of issuance, that person to possess cannabis for therapeutic purposes.

Copy link
XVII.

"Written certification" means documentation of a qualifying medical condition by a provider pursuant to rules adopted by the department pursuant to RSA 541-A for the purpose of issuing registry identification cards, after having completed a full assessment of the patient's medical history and current medical condition made in the course of a provider-patient relationship. Source. 2013, 242:1, eff. July 23, 2013. 2015, 195:1, eff. Sept. 4, 2015. 2016, 173:1, eff. Aug. 2, 2016; 247:1-3, eff. June 10, 2016. 2017, 47:1, eff. July 11, 2017; 125:1, eff. Aug. 15, 2017; 146:1, eff. June 16, 2017; 158:1, eff. Aug. 27, 2017. 2018, 219:3, eff. June 8, 2018; 360:1, eff. Aug. 31, 2018. 2019, 104:1, eff. Aug. 20, 2019; 306:4, eff. July 30, 2019; 344:1, 2, eff. Nov. 18, 2019. 2021, 46:1, 2, eff. June 24, 2021; 47:2, eff. July 24, 2021; 122:14-16, eff. Sept. 7, 2021; 193:1-4, eff. Oct. 9, 2021. 2023, 237:1, 2, eff. Oct. 7, 2023. 2024, 196:1, eff. Sept. 10, 2024; 283:1, eff. Sept. 24, 2024; 334:1, eff. Oct. 1, 2024. 2025, 105:1, eff. June 17, 2025.

Copy link

Source note

Source. 2013, 242:1, eff. July 23, 2013. 2015, 195:1, eff. Sept. 4, 2015. 2016, 173:1, eff. Aug. 2, 2016; 247:1-3, eff. June 10, 2016. 2017, 47:1, eff. July 11, 2017; 125:1, eff. Aug. 15, 2017; 146:1, eff. June 16, 2017; 158:1, eff. Aug. 27, 2017. 2018, 219:3, eff. June 8, 2018; 360:1, eff. Aug. 31, 2018. 2019, 104:1, eff. Aug. 20, 2019; 306:4, eff. July 30, 2019; 344:1, 2, eff. Nov. 18, 2019. 2021, 46:1, 2, eff. June 24, 2021; 47:2, eff. July 24, 2021; 122:14-16, eff. Sept. 7, 2021; 193:1-4, eff. Oct. 9, 2021. 2023, 237:1, 2, eff. Oct. 7, 2023. 2024, 196:1, eff. Sept. 10, 2024; 283:1, eff. Sept. 24, 2024; 334:1, eff. Oct. 1, 2024. 2025, 105:1, eff. June 17, 2025.

Source history

  • 2013, 242:1, eff. July 23, 2013
  • 2015, 195:1, eff. Sept. 4, 2015
  • 2016, 173:1, eff. Aug. 2, 2016; 247:1-3, eff. June 10, 2016
  • 2017, 47:1, eff. July 11, 2017; 125:1, eff. Aug. 15, 2017; 146:1, eff. June 16, 2017; 158:1, eff. Aug. 27, 2017
  • 2018, 219:3, eff. June 8, 2018; 360:1, eff. Aug. 31, 2018
  • 2019, 104:1, eff. Aug. 20, 2019; 306:4, eff. July 30, 2019; 344:1, 2, eff. Nov. 18, 2019
  • 2021, 46:1, 2, eff. June 24, 2021; 47:2, eff. July 24, 2021; 122:14-16, eff. Sept. 7, 2021; 193:1-4, eff. Oct. 9, 2021
  • 2023, 237:1, 2, eff. Oct. 7, 2023
  • 2024, 196:1, eff. Sept. 10, 2024; 283:1, eff. Sept. 24, 2024; 334:1, eff. Oct. 1, 2024
  • 2025, 105:1, eff. June 17, 2025

Related materials

Bill relationships

  • 2026 HB1235 reference

    or if the gift of cannabis is contingent upon a separate transaction for goods or services; or (c) Possessing or purchasing cannabis paraphernalia. III. Except as provided in RSA 126-X, any person under 21 years of age who knowingly possesses 3/4 ounce or less of cannabis, including adulterants or dilutants, shall be guilty of a violation, and subject to the penalties provided in paragraph V. IV. Exc

  • 2026 HB1235-FN reference

    or if the gift of cannabis is contingent upon a separate transaction for goods or services; or (c) Possessing or purchasing cannabis paraphernalia. III. Except as provided in RSA 126-X, any person under 21 years of age who knowingly possesses 3/4 ounce or less of cannabis, including adulterants or dilutants, shall be guilty of a violation, and subject to the penalties provided in paragraph V. IV. Exc

  • 2026 HB1446 amend

    ely on the basis of their lawful participation in this program. 2 New Section; Therapeutic Use of Cannabis Protections; Right to Purchase, Possess, and Transfer Firearms. Amend RSA 126-X by inserting after section 2 the following new section: 126-X:2-a Firearm Rights of Qualifying Patients. I. A qualifying patient, caregiver, or other person lawfully registered under this chapter shall not be deni

  • 2026 HB1796 reference · effective 2027-01-01

    PTER 126-XX THERAPEUTIC USE OF PSILOCYBIN 126-XX:1 Definitions. In this chapter: I. "Board" means the psilocybin production establishment licensing board created pursuant to RSA 126-XX:7. II. "Provider" means an approved medical or therapy provider licensed in this state who also holds a license from the department to recommend or provide services to qualified patients. III. "Department" means th

  • 2026 HB1796-FN reference · effective 2027-01-01

    PTER 126-XX THERAPEUTIC USE OF PSILOCYBIN 126-XX:1 Definitions. In this chapter: I. "Board" means the psilocybin production establishment licensing board created pursuant to RSA 126-XX:7. II. "Provider" means an approved medical or therapy provider licensed in this state who also holds a license from the department to recommend or provide services to qualified patients. III. "Department" means th

  • 2026 HB186 reference

    es to obtain a therapeutic cannabis endorsement that would allow them to serve qualifying patients without imposing the proposed excise tax. The bill would allow Alternative Treatment Centers, registered under RSA 126-X as not-for-profit entities, to convert to for-profit entities or operate as either for profit or not-for -profit. The bill includes a General Fund appropriation to the Department for the biennium ending June 3

  • 2026 HB186 amend

    axable cannabis shall be deposited in the cannabis fund and distributed pursuant to RSA 318-F:26. 27 ?Public Health; Use of Cannabis for Therapeutic Purposes; Definitions; Alternative Treatment Center. ? Amend RSA 126-X:1, I to read as follows: I. "Alternative treatment center" means a domestic business corporation organized under RSA 293-A, a domestic limited liability company organized under RSA 304-C, or a not-for-profit [en

  • 2026 HB186-FN-A reference

    318-E the following new chapter: CHAPTER 318-F REGULATION OF CANNABIS 318-F:1 Definitions. In this chapter: I. “Alternative treatment center” means an entity as defined in RSA 126-X:1, I. II. "Cannabis" or “marijuana” means all parts of the plant of the genus cannabis containing over 0.3 percent THC on a dry weight basis, whether growing or not, the resin extracted from any part of the plant, and e

  • 2026 HB186-FN-A reference

    of age or older, but not for resale. "Consumer" does not include a qualifying patient or designated caregiver purchasing cannabis from an alternative treatment center pursuant to RSA 126-X. XV. "Department" means the department of health and human services. XVI. “Designated caregiver” means “designated caregiver” as defined in RSA 126-X:1, VI. XVII. "Documentation" means all records, in any form, in

  • 2026 HB54 amend

    te for-profit. Be it Enacted by the Senate and House of Representatives in General Court convened: 1 ?Public Health; Use of Cannabis for Therapeutic Purposes; Definitions; Alternative Treatment Center. ? Amend RSA 126-X:1, I to read as follows: I. "Alternative treatment center" means a domestic business corporation organized under RSA 293-A, a domestic limited liability company organized under RSA 304-C, or a not-for-profit [en

  • 2026 HB54 amend

    es; Approvals of Statutory Conversion. ?Amend RSA 304-C:149 by inserting after paragraph VIII the following new paragraph: IX. ?In the case of the conversion of an alternative treatment center registered under RSA 126-X and organized pursuant to RSA 292, such conversion shall be approved by the board of directors in accordance with RSA 126-X:8, XX. 9 Effective Date. This act shall take effect 60 days after its passage. LBA 25

  • 2026 HB54-FN amend

    e Senate and House of Representatives in General Court convened: 1 ?Public Health; Use of Cannabis for Therapeutic Purposes; Definitions; Alternative Treatment Center. ? Amend RSA 126-X:1, I to read as follows: I. "Alternative treatment center" means a domestic business corporation organized under RSA 293-A, a domestic limited liability company organized under RSA 304-C, or a not-for-profit [entity] vol